Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Verrica Pharmaceuticals Inc (VRCA) USD0.0001

Sell:$14.17 Buy:$14.36 Change: $0.54 (3.94%)
Market closed |  Prices as at close on 1 March 2021 | Switch to live prices |
Sell:$14.17
Buy:$14.36
Change: $0.54 (3.94%)
Market closed |  Prices as at close on 1 March 2021 | Switch to live prices |
Sell:$14.17
Buy:$14.36
Change: $0.54 (3.94%)
Market closed |  Prices as at close on 1 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Verrica Pharmaceuticals Inc. is a United States-based clinical-stage medical dermatology company. The Company is focused on identifying, developing and commercializing pharmaceutical products for the treatment of skin diseases with unmet needs. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin. The Company also intends to develop second cantharidin-based product candidate, VP-103, for the treatment of plantar warts. The Company has completed one Phase II clinical trial of topical solution of cantharidin administered with the wooden stick part of a cotton-tipped swab. It also conducting another Phase II clinical trial of topical solution of cantharidin administered through applicator, which collectively refer to as VP-102, for the treatment of molluscum.

Contact details

Address:
10 N High St Ste 200
WEST CHESTER
19380-3014
United States
Telephone:
+1 (484) 4533300
Website:
www.verrica.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VRCA
ISIN:
US92511W1080
Market cap:
$354.62 million
Shares in issue:
25.87 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Paul Manning
    Chairman of the Board
  • Ted White
    President, Chief Executive Officer, Director
  • Brian Davis
    Chief Financial Officer
  • Christopher Hayes
    General Counsel, Corporate Secretary, Chief Legal Officer
  • Joe Bonaccorso
    Chief Commercial Officer
  • Patrick Burnett
    Chief Medical Officer
  • Bradley Catalone
    Head of Drug Development
  • Gary Goldenberg
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.